Gene Test Could Spot Dangerous Heart Condition
Posted on: Thursday, 22 December 2005, 12:00 CST
THURSDAY, Dec. 22 (HealthDay News) -- Researchers say they've developed a new gene-based test for long QT syndrome (LQTS), a heart condition that can predispose people to cardiac arrhythmias and sudden death.
A team from the S. Maugeri Foundation, in Pavia, Italy, conducted genetic testing on 430 LQTS patients and 1,115 of their family members, looking for mutations linked to the disorder.
They identified 235 different mutations -- including 138 new ones -- in 310 (72 percent) of the 430 patients. The team confirmed its findings by testing for the mutations in a separate group of 75 LQTS patients.
The findings appear in the Dec. 21 issue of the Journal of the American Medical Association.
"We have developed an approach to improve the efficiency of genetic screening for LQTS," the researchers wrote. The new method "may facilitate the access to genetic testing to a broader group of individuals, such as patients receiving drugs that prolong LQTS interval; family members of individuals with idiopathic ventricular fibrillation; and depending on results of further investigation, members of the general population to define the prevalence of known genetic variants of LQTS."
More information
The American Heart Association has more about LQTS.
SOURCE: Journal of the American Medical Association, news release, Dec. 21, 2005~HRT-~~GENT~~HATT~
Source: HealthSCOUT
Related Articles
- Clarient Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer
- Coalition for 21st Century Medicine Endorses 'Patient Access to Critical Lab Tests Act'
- Patient Side Point-of-Care Testing in the Emergency Department Enables Quicker Treatment Decisions for Patients With Chest Pain
- ChemGenex Investigators Present Data on Clinical Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients With the T315I Mutation at ASCO
- Roche Signs Exclusive Distribution Deal With DxS for K-RAS and EGFR Cancer Mutation Tests
- ChemGenex Investigators Present Data on Clinical Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients With the T315I Mutation at International Leukemia Conference
- ChemGenex Investigators Report Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients With the T315I Mutation
- ChemGenex Launches Multinational Phase 2/3 Study for CML Patients With the T315I Mutation; Reports Preclinical Activity in T315I+ CML
- Findings Reported From the First Study to Link Patients' Genetic Profiles With Their Clinical Outcomes After Cardiac Operations
- Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force
 |
 |
User Comments (0)
RSS Feeds